{"id":"intrathecal-triple","safety":{"commonSideEffects":[{"rate":null,"effect":"Chemical arachnoiditis"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection at injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This intrathecal formulation typically combines three chemotherapy agents (commonly methotrexate, cytarabine, and hydrocortisone) delivered directly into the cerebrospinal fluid via lumbar puncture or ventricular access. The direct CNS delivery achieves high local drug concentrations while minimizing systemic toxicity, targeting leukemic or lymphomatous cells in the central nervous system and meninges.","oneSentence":"Intrathecal triple is a combination chemotherapy regimen administered directly into the cerebrospinal fluid to treat hematologic malignancies and prevent or treat central nervous system involvement.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:52.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL) with CNS involvement or CNS prophylaxis"},{"name":"Acute myeloid leukemia (AML) with CNS involvement"},{"name":"Lymphoma with meningeal involvement"}]},"trialDetails":[{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":850},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":100},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":128},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT05809752","phase":"PHASE1","title":"A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-22","conditions":"Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer","enrollment":18},{"nctId":"NCT05146739","phase":"PHASE1","title":"Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-10-10","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome","enrollment":8},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT04501614","phase":"PHASE1, PHASE2","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-02-24","conditions":"Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)","enrollment":11},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT03792256","phase":"PHASE1","title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2019-04-11","conditions":"Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma","enrollment":12},{"nctId":"NCT06643000","phase":"NA","title":"Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-12-20","conditions":"Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation","enrollment":60},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT03194932","phase":"PHASE1","title":"Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-07-11","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT03349281","phase":"PHASE1","title":"Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL","status":"COMPLETED","sponsor":"Julio Barredo, MD","startDate":"2019-03-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":6},{"nctId":"NCT02776605","phase":"PHASE2","title":"Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2016-06","conditions":"ALL","enrollment":30},{"nctId":"NCT01861002","phase":"PHASE1","title":"A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2013-05-22","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood","enrollment":15},{"nctId":"NCT04905953","phase":"PHASE2, PHASE3","title":"Comparison Of Different Doses Of Intrathecal Neostigmine In Prevention Of Post-Dural Puncture Headache","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-02-01","conditions":"Headache","enrollment":274},{"nctId":"NCT03515200","phase":"PHASE1","title":"Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-04-20","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission","enrollment":12},{"nctId":"NCT03390387","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2015-11","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":4000},{"nctId":"NCT01953770","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2008-02","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":3000},{"nctId":"NCT01887587","phase":"PHASE1","title":"Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia","status":"TERMINATED","sponsor":"Ehab L Atallah","startDate":"2013-06","conditions":"Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":5},{"nctId":"NCT00928200","phase":"PHASE1","title":"Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2009-04-13","conditions":"Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase","enrollment":1},{"nctId":"NCT02680951","phase":"PHASE1","title":"Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2015-12","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT00098839","phase":"PHASE1, PHASE2","title":"Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-02","conditions":"Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":134},{"nctId":"NCT02270788","phase":"PHASE1","title":"Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-04-02","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT00096135","phase":"NA","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-11","conditions":"Leukemia","enrollment":168},{"nctId":"NCT02339350","phase":"PHASE2","title":"Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children","status":"UNKNOWN","sponsor":"The Korean Society of Pediatric Hematology Oncology","startDate":"2015-01","conditions":"Acute Lymphoblastic Leukemia, Child","enrollment":110},{"nctId":"NCT00795756","phase":"PHASE2, PHASE3","title":"Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Northern Italy Leukemia Group","startDate":"2008-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":145},{"nctId":"NCT00176462","phase":"PHASE2","title":"CINJALL: Treatment for Children With Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2001-02","conditions":"Acute Lymphocytic Leukemia","enrollment":60},{"nctId":"NCT00957320","phase":"PHASE1","title":"Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2009-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT00002970","phase":"PHASE2","title":"506U78 in Treating Patients With Refractory Hematologic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1997-06","conditions":"Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia","enrollment":148},{"nctId":"NCT00002704","phase":"PHASE2","title":"Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-01","conditions":"Leukemia","enrollment":156},{"nctId":"NCT00002798","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-08","conditions":"Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a)","enrollment":880},{"nctId":"NCT00991744","phase":"PHASE3","title":"Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)","status":"SUSPENDED","sponsor":"Nordic Society for Pediatric Hematology and Oncology","startDate":"2009-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DepoCyte","DepoCyt","Precortalon","Di-Adreson-F","Cytarabine"],"phase":"phase_3","status":"active","brandName":"Intrathecal triple","genericName":"Intrathecal triple","companyName":"Nordic Society for Pediatric Hematology and Oncology","companyId":"nordic-society-for-pediatric-hematology-and-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intrathecal triple is a combination chemotherapy regimen administered directly into the cerebrospinal fluid to treat hematologic malignancies and prevent or treat central nervous system involvement. Used for Acute lymphoblastic leukemia (ALL) with CNS involvement or CNS prophylaxis, Acute myeloid leukemia (AML) with CNS involvement, Lymphoma with meningeal involvement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}